EUCTR2012-001279-35-LV进行中（未招募）不适用
A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3-month formulation of triptorelin pamoate (11.25 mg) in patients with locally advanced or metastatic prostate cancer.
Ipsen Pharma S.A.S0 个研究点目标入组 120 人开始时间: 2012年9月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •. Histologically proven locally advanced or metastatic prostate
- •cancer who are suitable for androgen deprivation therapy
- •2. Male aged =18 years old
- •3. Screening testosterone level of >125 ng/dL
- •4. Life expectancy of greater than 12 months in the judgement
- •of the Investigator
- •5. Eastern Cooperative Oncology Group (ECOG) performance
- •status of 0-1
- •6. Willing to give signed informed consent freely
- •7. Able to adhere to the study visit schedule and other protocol
- •requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •1. Prior hormonal therapy for prostate cancer
- •2. Prior surgery or radiotherapy of prostate cancer with curative
- •intent unless disease is verified by a rising PSA concentration on follow-up (elevated PSA values on last two tests conducted at least a month apart) and the patient is eligible for androgen deprivation therapy
- •3. Presence or history of any other malignancy except for
- •non-melanoma skin cancer adequately treated at least 2 years
- •before study entry
- •4. Painful local bone lesions or spinal lesions which may lead
- •to compression
- •5. History of myocardial infarction, percutaneous coronary
- •intervention, acute coronary syndrome, coronary artery
- •bypass graft, Class III/IV congestive heart failure,
- •cerebrovascular accident, transient ischaemic attack, or limb
- •claudication at rest, within six months prior to start of study
- •treatment and ongoing symptomatic dysrhythmias, unstable
- •angina, uncontrolled hypertension, and untreated atrial or
- •uncontrolled ventricular arrhythmias
- •6. Any condition in opinion of the Investigator, including other
- •active or latent infections, medical or psychiatric conditions,
- •or the presence of laboratory abnormalities, which could
- •confound the ability to interpret data from the study,
- •compromises the objective of the study or places the patient
- •at unacceptable risk if he participates in the study
- •7. Abnormal haematological, hepatic or renal functions:
- •Haemoglobin <9 g/dL, absolute neutrophil count =1.5 x 109/L or platelets =100 x 109/L
- •Serum creatinine =1.5 times the upper limit of normal (ULN)
- •Aspartate aminotransferase or alanine aminotransferase >2.5 times the ULN
- •8. Known hypersensitivity to the study treatment, to any of its
- •9. Known active use of recreational drug or alcohol dependence
- •in the opinion of the Investigator
- •10. Any current use or use within six months prior to start of
- •treatment, of medications which are known to affect the
- •metabolism and/or secretion of androgenic hormones: e.g.
- •ketoconazole, aminoglutethimide, oestrogens, and
- •progesterone
- •11. Use of systemic corticosteroids (inhaled corticosteroids and
- •topical application of corticosteroids are permitted)
- •12. Aged =90 years for the main study and =80 years for those
- •included in the PK population
- •13. Participation in any other study or receipt of any
- •investigational compound in the 30 days (or five times the
- •elimination half life if this is longer) prior to study entry
- •14. Any skin or other condition that may preclude s.c. injection
- •administration
- •15. Known brain or epidural metastases.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate the efficay, safety and local tolerability of triptorelin pamoate (11,25mg) injected sub cuteanously in patients with (locally advanced or metastatic) prostate cancer.EUCTR2012-001279-35-PLIpsen Pharma S.A.S120
进行中（未招募）
不适用
Study to evaluate the efficay, safety and local tolerability of triptorelin pamoate (11,25mg) injected sub cuteanously in patients with (locally advanced or metastatic) prostate cancer.ocally advanced or metastatic prostate cancerMedDRA version: 16.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001279-35-BGIpsen Pharma S.A.S120
进行中（未招募）
1 期
AThis study will enroll subjects with transfusion dependent beta-thalassemia, who have a beta0/beta0 genotype, defined by a history of at least 100 mL/kg/year of packed red blood cells (pRBCs) or = 8 transfusions of pRBCs per year in the 2 year preceding enrollment.MedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2016-003611-35-DEbluebird bio, Inc.18
进行中（未招募）
1 期
AEUCTR2015-004122-33-DEbluebird bio, Inc.23
进行中（未招募）
1 期
AEUCTR2015-004122-33-GRbluebird bio, Inc.15